GlycoMimetics (GLYC) Tops Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. META
3. SPY
4. ANT
5. CART
6. FFAI
7. TSLA
8. FFR
9. XNCR
10. AZN

Go back to GlycoMimetics (GLYC) Tops Q2 EPS by 4c

GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2022

August 3, 2022 7:00 AM EDT

U.S. Food and Drug Administration (FDA) Clearance of Investigational New Drug (IND) application to study GMI-1687 in Sickle Cell Disease (SCD) received in June The Company previously disclosed and will continue to update its projection of mid-year 2023 for the survival events trigger for its pivotal Phase 3 trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML) Progress in data collection now enables the Company to share a comparison of the demographics of the pivotal Phase 3 study to those of the completed Phase 2 study Conference call and webcast today... More